SGLT2 Inhibitor Dapagliflozin Increases Skeletal Muscle and Brain Fatty Acid Uptake in Individuals With Type 2 Diabetes: A Randomized Double-Blind Placebo-Controlled Positron Emission Tomography Study.
Aino Latva-RaskuEleni RebelosJouni TuiskuRichard AarnioAchol A BhowmikHelmi KeskinenSanna LaurilaMinna Lahesmaa-HattingLaura PekkarinenHenrik IsacksonAnna Kaarina KirjavainenJukka KoffertKerstin HeurlingLauri NummenmaaEleuterio FerranniniJonas OldgrenJan OscarssonPirjo NuutilaPublished in: Diabetes care (2024)
Six weeks of treatment with dapagliflozin increases skeletal muscle and brain FA uptake, partly driven by a rise in free FA availability. This finding is in accordance with previous indirect measurements showing enhanced FA metabolism in response to SGLT2 inhibition and extends the notion of a shift toward increased FA use to muscle and brain.